Test chemotherapy without radiation for early Hodgkin lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This Phase 2 study tests whether you can treat early-stage Hodgkin lymphoma with chemotherapy while avoiding radiation. It may help reduce radiation-related side effects if the treatment controls the cancer effectively.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re 18–60 years old
- You have newly diagnosed (treatment-naïve) classical Hodgkin lymphoma in stage I or II and it is not bulky
- You are well enough to do daily activities (ECOG 0–2)
- Your blood counts are high enough (hemoglobin > 8, neutrophils ≥ 1,000, platelets ≥ 100,000)
- Your kidney and liver tests are within limits (creatinine under 2.0 mg/dL or clearance > 40; ALT/AST < 3× normal; bilirubin < 2× normal unless Gilbert syndrome)
- If you can become pregnant or are male with a partner who can become pregnant, you can use effective birth control as instructed
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a lower dose of radiation, guided by PET scans, is safe and effective for people with early-stage but unfavorable Hodgkin lymphoma. It aims to reduce side effects while keeping the treatment strong.
This Phase 2 trial tests tislelizumab (an immune therapy) in people with newly diagnosed classical Hodgkin lymphoma who cannot safely get standard chemotherapy. It aims to see how well the treatment works and whether it is safe for older adults and others with health limits.
This study tests a combination of a newer immunotherapy drug (nivolumab) with standard chemotherapy (AVD) in children, teens, and young adults with newly diagnosed, early-stage Hodgkin lymphoma—a blood cancer affecting lymph nodes. The goal is to see if adding immunotherapy improves outcomes while being tolerable for this age group.
This Phase 3 trial studies whether adding brentuximab vedotin to standard chemotherapy improves outcomes for people with newly diagnosed early-stage classical Hodgkin lymphoma. It may help reduce the chance the cancer returns or improves how well treatment works.
This trial tests if proton beam radiation can effectively treat Hodgkin lymphoma while reducing side effects. It is for people with early-stage disease who have already completed chemotherapy and need radiation.
This trial tests a newer, lower-dose immunotherapy combination (AVD plus nivolumab) against a standard intensive chemo regimen (BEACOPP) that is adjusted based on PET scan results. It is for people with advanced classical Hodgkin lymphoma that has not been treated before.
Hear when a new Hodgkin Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.